RELMADA THERAPEUTICS, INC.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Christopher L. JacobsHouse · R · NY |
RLMDRELMADA THERAPEUTICS, INC. · Stock |
Sale $1,001 - $15,000 |
Jan 20, 2023 | Dec 12, 2022 | Filing ↗ |
Christopher L. JacobsHouse · R · NY |
RLMDRELMADA THERAPEUTICS, INC. · Stock |
Purchase $1,001 - $15,000 |
Dec 12, 2022 | Nov 8, 2022 | Filing ↗ |
Whale Activity
- Increased51
- New20
- Held25
- Decreased34
- Closed12
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| Janus Henderson Group Ltd. | 11.2M | $42.0M | — |
| BlackRock, Inc. | 7.6M | $28.6M | increased |
| Venrock Adviser, LLC | 7.4M | $28.1M | increased |
| Spruce Street Capital LP | 6.9M | $26.1M | increased |
| Jones Hill Capital LP | 5.2M | $19.7M | increased |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.8M | $18.0M | held |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4M | $16.4M | decreased |
| AMERIPRISE FINANCIAL INC | 3.7M | $14.0M | — |
| Sio Capital Management, LLC | 3.6M | $13.7M | increased |
| Squadron Capital Management LLC | 3.5M | $13.2M | decreased |
| MILLENNIUM MANAGEMENT LLC | 3.3M | $12.6M | increased |
| STATE STREET CORP | 3.3M | $12.5M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Shenouda MagedChief Financial Officer | Purchase | +79.8K | $4.25 | $339K | Sep 10, 2026 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +100.0K | $4.10 | $410K | Sep 10, 2026 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +120.2K | $4.20 | $505K | Sep 9, 2026 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +100.0K | $4.18 | $418K | Sep 9, 2026 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +27.5K | $4.12 | $113K | Dec 15, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +11.7K | $4.12 | $48K | Dec 15, 2025 | Form 4 ↗ |
| Ence ChuckCAO and COO | Purchase | +136.0K | $2.20 | $299K | Nov 5, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +272.5K | $2.20 | $600K | Nov 5, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +500.0K | $2.20 | $1.1M | Nov 5, 2025 | Form 4 ↗ |
| Kelly Paul EdwardChief Operating Officer · Director | Purchase | +90.0K | $2.20 | $198K | Nov 5, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +56.0K | $0.74 | $41K | Aug 28, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +129.5K | $0.67 | $87K | Aug 27, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +80.5K | $0.62 | $50K | Aug 26, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +60.0K | $0.52 | $31K | May 20, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +147.7K | $0.56 | $83K | May 20, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +90.0K | $0.49 | $44K | May 19, 2025 | Form 4 ↗ |
| TRAVERSA SERGIOChief Executive Officer · Director | Purchase | +30.0K | $0.50 | $15K | May 19, 2025 | Form 4 ↗ |
| Kelly Paul EdwardChief Operating Officer · Director | Purchase | +200.0K | $0.43 | $86K | May 16, 2025 | Form 4 ↗ |
| Shenouda MagedChief Financial Officer | Purchase | +50.0K | $0.44 | $22K | May 16, 2025 | Form 4 ↗ |
| Ence ChuckCA and CO | Purchase | +229.0K | $0.45 | $103K | May 16, 2025 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $21.9M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 2.1M | $14.4M | 0.02% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $8.3M | 0.01% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST | 1.0M | $7.0M | 0.39% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 865.6K | $6.0M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.0M | $5.5M | 0.02% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 655.1K | $4.5M | 1.06% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 788.7K | $4.2M | 0.36% | Jul 31, 2026 |
| AdvisorShares Psychedelics ETF AdvisorShares Trust | 438.9K | $3.0M | 6.84% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 541.6K | $2.4M | 0.01% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list RLMD's shares (CUSIP 75955J402), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- William BlankSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
Nov 16, 2026 · ↗ - Matthew SesterhennSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
Nov 16, 2026 · ↗ - Squadron Capital Management LLCSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
Nov 16, 2026 · ↗ - Squadron Master Fund LPSCHEDULE 13G/A · passive (13G) · 3.5M shares3.3%
Nov 16, 2026 · ↗ - William BlankSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - Matthew SesterhennSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - Squadron Capital Management LLCSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - Squadron Master Fund LPSCHEDULE 13G/A · passive (13G) · 7.3M shares7.0%
Aug 14, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G · passive (13G) · 7.4M shares7.0%
Jul 29, 2026 · ↗ - Israel A. EnglanderSCHEDULE 13G · passive (13G) · 4.6M shares4.4%
Jun 22, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming RELMADA THERAPEUTICS, INC. as the client.
- THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q4$30K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q3$30K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q2$20K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2022 Q1$20K
Filing ↗ - THE KPM GROUP DC LLCRELMADA THERAPEUTICS, INC. · 2021 Q4$30K
Filing ↗
Government Contracts
No federal contract awards found for RELMADA THERAPEUTICS, INC..
U.S. Patents
No USPTO patent applications found for RELMADA THERAPEUTICS, INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M | -$125.8M |
| Diluted EPS | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 |
| Operating cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M |
| Cash and equivalents | $3.5M | $3.9M | $4.1M | $5.4M | $44.4M |
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M |
| Shareholders' equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M |
As RELMADA THERAPEUTICS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 19, 2026 ↗
Stock Splits
- 1-for-4Reverse splitSep 30, 2019
- 1-for-5Reverse splitAug 12, 2015
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 7.01, 9.01Reg FD disclosureNov 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureNov 12, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 6, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureJul 28, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteMay 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 12, 2026
EDGAR ↗

